On March 9, 2022 Compugen Ltd. (Nasdaq: CGEN),("Compugen," the "Company"), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported the presentation of new research suggesting that targeting PVRIG and TIGIT holds promise for treating multiple myeloma (Press release, Compugen, MAR 9, 2022, View Source [SID1234609835]). The research on the expression of PVRIG and TIGIT pathway in the bone marrow of multiple myeloma patients conducted in collaboration with Dr. James Berenson and his team at the Institute for Myeloma and Bone Cancer Research, will be presented as a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting to take place on April 8-13, 2022, in New Orleans, Louisiana.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We continue to lead groundbreaking research on the biology of the key targets of the DNAM-1 axis PVRIG and TIGIT. The data we will present at the AACR (Free AACR Whitepaper) annual meeting places the DNAM-1 axis as a potential dominant therapeutic pathway in multiple myeloma, where immunotherapy has shown limited success. The data demonstrate the potential of combining TIGIT and PVRIG inhibitors in the treatment of patients with multiple myeloma," said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. "These data support our hypothesis that therapies targeting the DNAM-1 axis may provide new treatment options for certain cancer patients."
Poster details
Presentation Date: April 10, 2022
Poster Number: Poster #4934
Session Title: Immune Checkpoints
Poster Title: The expression of the PVRIG/TIGIT pathway is dominant in the bone marrow of patients with multiple myeloma
The abstract is available on Compugen’s website at www.cgen.com.